| 1/3 | US=22 / Urologia Motzer RJ. Sunitinib and axitinib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 151-65. ISBN 978-1-58829-737-2. SUNITINIB; SU11248; AXITINIBE; CARCINOMA DE CELULAS RENAIS; SUTENT; AG-013736 |
| 2/3 | US=50 / Câncer Rugo HS, Lin AYJ. Targeted therapy for breast cancer: a focus on HER2/neu and antiangiogenic therapy. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 497-509. ISBN 978-1-60327-086-1. TERAPIA-ALVO PARA CANCER DE MAMA; HER2/NEU E TERAPIA ANTIANGIOGENICA; CANCER DE MAMA METASTATICO; HER2/NEU; TRASTUZUMAB; LAPATINIB; BEVACIZUMAB; SUNITINIB; ANTIANGIOGENICO; TERAPIA-ALVO |
| 3/3 | US=50 / Câncer Ryan CJ. Development in the management of genitourinary malignancies: prostate cancer and renal cell carcinoma. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 533-44. ISBN 978-1-60327-086-1. DOENCAS MALIGNAS DO APARELHO GENITURINARIO; CANCER DE PROSTATA; CARCINOMA DE CELULAS RENAIS; CASTRACAO-RESISTENTE O CANCER DE PROSTATA; ANDROGENIOS ADRENAIS; IMUNOTERAPIA; FASE II; ABIRATERONA; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; QUIMIOTERAPIA; GVAX; IPILIMUMAB; IXABEPILONA; SATRAPLATIN; SIPULEUCEL-T; VEGF; SUNITINIB; SORAFENIB |